All In Biotech

Drug Trial Radar · NCT04581629

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1

Last checked: Nov 20, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

13

Actual

Start

Sep 20, 2020

Primary completion

Sep 7, 2023

Study completion Sep 7, 2023

Sponsor

Sponsor type
Industry
First posted
Oct 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety, tolerability and effectiveness of encaleret in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Conditions

  • Autosomal Dominant Hypocalcemia (ADH)
  • Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Interventions

  • EncaleretDrug

    Tablets administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Periods 1, 2 and 3: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 up to 16 months
  2. Period 3: Change From Baseline in Albumin-Corrected Blood Calcium Concentrations (cCa)Time frame: Baseline, Week 24
  3. Period 3: Rate of Urinary Calcium ExcretionTime frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health (NIH) Clinical Center

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.